Clinicians need to be informed about therapeutic advances and necessary supportive care precautions to aid in their effective and safe incorporation into clinical practice for the appropriate AML patient subpopulations.

Clinicians may find it difficult to determine which single- or multi-agent therapies are most effective for patients with different kidney cancer histologies and risk groups. The NCCN Categories of Preference and Categories of Evidence and Consensus help to stratify the most effective treatment regimens by histology and risk status.

Clinicians may be challenged when considering a trial of upfront systemic therapy alone for brain metastases, and a multidisciplinary discussion between medical and radiation oncology is recommended.

Marginal zone lymphomas (MZLs) represent a clinical challenge due to their heterogeneity, and the relative rarity of individual subtypes has largely precluded the use of standard treatment approach across all subtypes. Educating clinicians about the biology of MZLs, novel therapeutic approaches, and special considerations will help them to develop an individualized treatment plan to optimize clinical outcomes.